<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="96321"><DrugName>xenon (inhaled, brain ischemia/perinatal asphyxia/cardiac arrest), NeuroproteXeon</DrugName><DrugSynonyms><Name><Value>xenon</Value></Name><Name><Value>xenon (inhaled, brain ischemia/perinatal asphyxia/cardiac arrest), NeuroproteXeon</Value></Name><Name><Value>Xenex</Value></Name><Name><Value>7440-63-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1005207">NeuroproteXeon</CompanyOriginator><CompaniesPrimary><Company id="1085756">Mallinckrodt plc</Company><Company id="1005207">NeuroproteXeon</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1005207" type="Company"><TargetEntity id="5000161626" type="organizationId">Protexeon Ltd</TargetEntity></SourceEntity><SourceEntity id="1085756" type="Company"><TargetEntity id="5038068684" type="organizationId">Mallinckrodt Plc</TargetEntity></SourceEntity><SourceEntity id="1557" type="ciIndication"><TargetEntity id="I46" type="ICD10"></TargetEntity><TargetEntity id="427.5" type="ICD9"></TargetEntity><TargetEntity id="10007515" type="MEDDRA"></TargetEntity><TargetEntity id="D006323" type="MeSH"></TargetEntity><TargetEntity id="-502675543" type="omicsDisease"></TargetEntity><TargetEntity id="2007" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1635" type="ciIndication"><TargetEntity id="D020925" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="1636" type="ciIndication"><TargetEntity id="I67.82" type="ICD10"></TargetEntity><TargetEntity id="D002545" type="MeSH"></TargetEntity><TargetEntity id="-137109010" type="omicsDisease"></TargetEntity><TargetEntity id="91" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3645" type="ciIndication"><TargetEntity id="10051624" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1246" type="Action"><TargetEntity id="2719" type="Mechanism">NMDA Glycine B Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1557">Cardiac arrest</Indication><Indication id="1635">Brain hypoxia-ischemia</Indication><Indication id="1636">Brain ischemia</Indication><Indication id="3645">Cardiac reperfusion injury</Indication></IndicationsPrimary><ActionsPrimary><Action id="1246">NMDA glycine antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1615">Neuroprotectant</Action><Action id="2659">Cardioprotectant</Action><Action id="449">Antiarrhythmic agent</Action></ActionsSecondary><Technologies><Technology id="616">Inhalant formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C1B</Code><Name>ANTI-ARRHYTHMICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-14T05:53:02.000Z</LastModificationDate><ChangeDateLast>2019-01-16T00:00:00.000Z</ChangeDateLast><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1005207" linkType="Company"&gt;NeuroproteXeon&lt;/ulink&gt; (presumed to be formerly known as Protexeon), a spin-out from &lt;ulink linkID="23577" linkType="Company"&gt;Imperial College London&lt;/ulink&gt;, and licensee &lt;ulink linkID="1085756" linkType="Company"&gt;Mallinckrodt&lt;/ulink&gt; are developing Xenex, inhaled xenon gas, which binds to N-methyl-D-aspartate (NMDA) receptors, as a neuroprotectant for the  potential reduction of ischemic brain injury and improvement of neurological outcome in cardiac arrest patients (post cardiac arrest syndrome), and treatment of hypoxic ischemic encephalopathy following perinatal asphyxia   [&lt;ulink linkID="1646151" linkType="Reference"&gt;1646151&lt;/ulink&gt;], [&lt;ulink linkID="1649753" linkType="Reference"&gt;1649753&lt;/ulink&gt;];  [&lt;ulink linkID="1663081" linkType="Reference"&gt;1663081&lt;/ulink&gt;],  [&lt;ulink linkID="1743743" linkType="Reference"&gt;1743743&lt;/ulink&gt;], [&lt;ulink linkID="1937462" linkType="Reference"&gt;1937462&lt;/ulink&gt;], [&lt;ulink linkID="1966684" linkType="Reference"&gt;1966684&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2018, a phase III out-of-hospital cardiac arrest (OHCA) trial was initiated [&lt;ulink linkID="1937462" linkType="Reference"&gt;1937462&lt;/ulink&gt;]. At that  time,  interim analysis of the trial was expected  to occur in 4Q19 and the  trial was planned to complete in 2020 [&lt;ulink linkID="2106273" linkType="Reference"&gt;2106273&lt;/ulink&gt;]. In February 2012, a phase I/II trial began in newborn infants with perinatal asphyxial encephalopathy; the trial completed in September 2014  [&lt;ulink linkID="1649758" linkType="Reference"&gt;1649758&lt;/ulink&gt;].  In October 2017, subject to successful phase III trial completion, the drug and delivery device combination was anticipated to be approved in the US  in late 2020 [&lt;ulink linkID="1966684" linkType="Reference"&gt;1966684&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2018, the FDA granted Fast Track status to Xenex for the treatment of post cardiac arrest [&lt;ulink linkID="2066200" linkType="Reference"&gt;2066200&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2017, assuming successful completion of the planned pivotal phase III trial, the drug and delivery device combination was anticipated to be approved in the US  in late 2020 [&lt;ulink linkID="1966684" linkType="Reference"&gt;1966684&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, the FDA granted xenon gas Orphan designation for the treatment of hypoxic ischemic encephalopathy [&lt;ulink linkID="1649753" linkType="Reference"&gt;1649753&lt;/ulink&gt;]. In May 2015, the FDA awarded the drug Orphan designation for the improvement of neurological outcome in hospitalized cardiac arrest patients [&lt;ulink linkID="1663081" linkType="Reference"&gt;1663081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2015, the COMP of the EMA recommended granting xenon Orphan designation for the  treatment of perinatal asphyxia [&lt;ulink linkID="1646151" linkType="Reference"&gt;1646151&lt;/ulink&gt;]; in April 2015, Orphan status was granted [&lt;ulink linkID="1661864" linkType="Reference"&gt;1661864&lt;/ulink&gt;]. In September 2016, the COMP recommended granting the product Orphan designation for the treatment of ischemia reperfusion injury associated with cardiac arrest [&lt;ulink linkID="1798089" linkType="Reference"&gt;1798089&lt;/ulink&gt;]; in October 2016, the Orphan designation was granted [&lt;ulink linkID="1874733" linkType="Reference"&gt;1874733&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PREMAKETING STUDIES&lt;/subtitle&gt;&lt;subtitle&gt;Cardiac arrest&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In January 2016, a pivotal phase III study in patients with OHCA was planned. The primary outcome would be survival from cardiac arrest.  At  that time,   the  study was planned to be completed in less than two years following the FDA/EMA approval and the patient enrollment was expected to initiate in January 2017 [&lt;ulink linkID="1747360" linkType="Reference"&gt;1747360&lt;/ulink&gt;]. In March 2016, the company was seeking approval from the US FDA to initiate the pivotal phase III   trial later that year [&lt;ulink linkID="1743743" linkType="Reference"&gt;1743743&lt;/ulink&gt;]. In December 2016, the interventional, prospective, randomized, parallel group assigned, multicenter phase III study (&lt;ulink linkID="301036" linkType="Protocol"&gt;NCT03176186&lt;/ulink&gt;; XePOHCAS; XePOHCAS Ph III) was planned to initiate in the US and Denmark in adult patients (expected n = 1436) with OHCA, to compare standard OHCA intensive care to xenon by inhalation. At that time, the study was to begin in October 2017 and complete in October 2019 [&lt;ulink linkID="1937462" linkType="Reference"&gt;1937462&lt;/ulink&gt;]. By October 2017, an FDA special protocol assessment had been approved and at that time the trial was to begin in early 2018. The primary endpoint included improved 30-day survival and improved functional outcomes and an interim analysis was expected at 50% of trial completion of the primary endpoint follow up [&lt;ulink linkID="1966684" linkType="Reference"&gt;1966684&lt;/ulink&gt;]. In August 2018, the trial was expected to commence in the coming months with first patients enrolled in the US [&lt;ulink linkID="2066200" linkType="Reference"&gt;2066200&lt;/ulink&gt;]. In December 2018, the trial was initiated [&lt;ulink linkID="1937462" linkType="Reference"&gt;1937462&lt;/ulink&gt;]. At that time, interim analysis of the trial was expected in 4Q19 and the  trial was planned to complete in 2020 [&lt;ulink linkID="2106273" linkType="Reference"&gt;2106273&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2009, a randomized, open-label, phase II trial (&lt;ulink url="NCT00879892"&gt;NCT00879892&lt;/ulink&gt;; Eudra CT2009-009505-25) began to study the effect of xenon, in combination with therapeutic hypothermia, on the brain and on neurological outcome following brain ischemia in cardiac arrest patients (n = 110) in the US and Finland. The trial completed in September 2014 [&lt;ulink linkID="1803209" linkType="Reference"&gt;1803209&lt;/ulink&gt;]. In March 2016, data from the trial with out-of-hospital cardiac arrest (OHCA) patients were published. Data showed that the xenon and oxygen group suffered significantly less (p = 0.006) white matter brain damage, assessed by MRI, when compared to patients treated with hypothermia alone. The 6-month mortality rate was 27.3% in the xenon/oxygen group and 34.5% in the hypothermia alone group [&lt;ulink linkID="1743743" linkType="Reference"&gt;1743743&lt;/ulink&gt;], [&lt;ulink linkID="1743878" linkType="Reference"&gt;1743878&lt;/ulink&gt;], [&lt;ulink linkID="1966684" linkType="Reference"&gt;1966684&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Perinatal asphyxial encephalopathy&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In July 2009, a randomized, single-blind, phase I/II  trial (&lt;ulink linkID="226633" linkType="Protocol"&gt;NCT00934700&lt;/ulink&gt;; prot-002-2009; EudraCT 2009-014344-11; TOBYXe) was planned to start in September 2009 to study the safety and efficacy of 30% xenon (balanced with oxygen and air) inhaled for 24 h in newborn infants (estimated n = 130) in the UK with perinatal asphyxial encephalopathy. The trial would assess whether a combination of hypothermia and inhaled xenon could preserve cerebral metabolism and structure. The trial started in February 2012 and completed in September 2014 (n = 92) [&lt;ulink linkID="1649758" linkType="Reference"&gt;1649758&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-21T00:00:00.000Z</StatusDate><Source id="2106273" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-21T00:00:00.000Z</StatusDate><Source id="2106273" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-21T00:00:00.000Z</StatusDate><Source id="2106273" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-21T00:00:00.000Z</StatusDate><Source id="2106273" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1635">Brain hypoxia-ischemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-29T00:00:00.000Z</StatusDate><Source id="1649758" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1636">Brain ischemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-05-31T00:00:00.000Z</StatusDate><Source id="1803209" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1636">Brain ischemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="FI">Finland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1636">Brain ischemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-05-31T00:00:00.000Z</StatusDate><Source id="1803209" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="FI">Finland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1636">Brain ischemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="FI">Finland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-05-31T00:00:00.000Z</StatusDate><Source id="1803209" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3645">Cardiac reperfusion injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-06T00:00:00.000Z</StatusDate><Source id="1798089" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3645">Cardiac reperfusion injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005207">NeuroproteXeon</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1005207">NeuroproteXeon</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1635">Brain hypoxia-ischemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1649758" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085756">Mallinckrodt plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-02T00:00:00.000Z</StatusDate><Source id="1966684" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005207">NeuroproteXeon</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-05-31T00:00:00.000Z</StatusDate><Source id="1803209" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005207">NeuroproteXeon</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1557">Cardiac arrest</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-06T00:00:00.000Z</StatusDate><Source id="1798089" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1005207">NeuroproteXeon</OwnerCompany><Country id="US">US</Country><Indication id="1557">Cardiac arrest</Indication><AwardedIndication>Treatment of Cardiac arrest</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-23T00:00:00.000Z</MileStoneDate><Source id="2066200" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1005207">NeuroproteXeon</OwnerCompany><Country id="EU">EU</Country><Indication id="3645">Cardiac reperfusion injury</Indication><AwardedIndication>Treatment of ischaemia reperfusion injury associated with cardiac arrest</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-14T00:00:00.000Z</MileStoneDate><Source id="1874733" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1005207">NeuroproteXeon</OwnerCompany><Country id="EU">EU</Country><Indication id="3645">Cardiac reperfusion injury</Indication><AwardedIndication>Treatment of ischaemia reperfusion injury associated with cardiac arrest</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-08T00:00:00.000Z</MileStoneDate><Source id="1798089" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1005207">NeuroproteXeon</OwnerCompany><Country id="US">US</Country><Indication id="1635">Brain hypoxia-ischemia</Indication><AwardedIndication>To improve neurological outcome in hospitalized cardiac arrest patients.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-18T00:00:00.000Z</MileStoneDate><Source id="1663081" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1005207">NeuroproteXeon</OwnerCompany><Country id="EU">EU</Country><Indication id="1635">Brain hypoxia-ischemia</Indication><AwardedIndication>Treatment of perinatal asphyxia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-24T00:00:00.000Z</MileStoneDate><Source id="1661864" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1005207">NeuroproteXeon</OwnerCompany><Country id="EU">EU</Country><Indication id="1635">Brain hypoxia-ischemia</Indication><AwardedIndication>Treatment of perinatal asphyxia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-25T00:00:00.000Z</MileStoneDate><Source id="1646151" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1005207">NeuroproteXeon</OwnerCompany><Country id="US">US</Country><Indication id="1635">Brain hypoxia-ischemia</Indication><AwardedIndication>Treatment of hypoxic ischemic encephalopathy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-03T00:00:00.000Z</MileStoneDate><Source id="1649753" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01435"><Name>NMDA receptor</Name><SwissprotNumbers><Swissprot>O60391</Swissprot><Swissprot>Q8TCU5</Swissprot><Swissprot>Q8VHN2</Swissprot><Swissprot>Q91ZU9</Swissprot><Swissprot>Q9R1M7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1005207">NeuroproteXeon</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="1085756">Mallinckrodt plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23123">Cato Holding Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000490">Linde AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>[Xe]</Smiles></StructureSmiles><Deals><Deal id="159560" title="Cato Research to provide NeuroproteXeon CRO services related to phase III trial of xenon for hypoxic ischemic encephalopathy following perinatal asphyxia"></Deal><Deal id="243067" title="Mallinckrodt to develop and commercialize NeuroproteXeon's xenon gas for patients resuscitated after a cardiac arrest in the US, Canada, Japan and Australia"></Deal><Deal id="246862" title="Linde to distribute NeuroproteXeon's XENEX for PCAS in European Union including United Kingdom, Switzerland, Norway and Iceland           "></Deal></Deals><PatentFamilies><PatentFamily id="1382727" number="WO-2006018655" title="Use of xenon as neuroprotectant in a neonatal subject"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NeuroproteXeon" id="1005207"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Imperial College London" id="23577"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>